US Pharm. 2012;37(8):54.
Impax Laboratories, Inc., and TOLMAR, Inc., announced that they would collaborate on a multiproduct agreement for the development, supply, and distribution of generic forms of topical prescription drug products. As part of the agreement, TOLMAR will supply up to nine currently approved and marketed products, and Impax’s generics division, Global Pharmaceuticals, will commercialize these products following a short transition period. According to Wolters Kluwer Health, total U.S. brand and generic sales of these nine multisource products were approximately $378 million in the 12 months ended May 2012. The agreement also includes two additional generic forms of topical prescription drug products; one is currently in development and the other is a first-to-file Abbreviated New Drug Application pending FDA approval.